Ryan Card
General Counsel
Ryan Card joined A2 Biotherapeutics in July 2024 as general counsel. He leads the legal function for the company.
Before joining A2 Bio, Ryan served as executive vice president, general counsel and chief compliance officer of Urovant Sciences until the company’s merger into Sumitomo Pharma America in 2023. In this role, he led Urovant’s legal and compliance functions through the successful launch of the company’s first commercial product in the United States, GEMTESA® (vibegron). Prior to joining Urovant, Ryan was executive director, senior counsel with Allergan plc, where he worked as chief counsel for the company’s neurology, eye care, and urology business units, which included the company’s BOTOX therapeutic franchise. He also led the company’s commercial contracting function.
Previously, Ryan was a senior litigation associate with Gibson, Dunn & Crutcher, LLP. He earned a bachelor of science degree from the University of Utah and his law degree from Brigham Young University Law School.